SAN DIEGO, Nov. 17, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced it will be expanding its facilities by opening a satellite office on Gateway Boulevard in South San Francisco. Halozyme is headquartered in San Diego and currently has approximately 200 employees.
"Given the company's focus in oncology and growth trajectory, a satellite office in San Francisco is an important step to help us attract additional talented team members whose focus will be to expand our clinical programs and advance towards our goal of commercializing our investigational new drug, PEGPH20," said Helen Torley, president and CEO. "The Bay Area satellite location will give us the ability to augment our already strong San Diego work force."
In addition to the ongoing Phase 2 Study 202 of PEGPH20 in combination with gemcitabine and ABRAXANE® (nab-paclitaxel) in pancreatic cancer, and the Phase 1b/2 study of PEGPH20 in combination with docetaxel in Non-Small Cell Lung Cancer (NSCLC). Halozyme recently announced that it has initiated a clinical trial for a phase 1b/2 study evaluating its investigational new drug PEGPH20 in combination with KEYTRUDA® (pembrolizumab) in NSCLC and Gastric Cancer. Halozyme also plans to initiate a Phase 3 trial of PEGPH20 in combination with gemcitabine and ABRAXANE® (nab-paclitaxel) in pancreatic cancer by the end of Q1 2016. PEGPH20 (PEGylated recombinant human hyaluronidase) targets hyaluronan (HA), a glycosaminoglycan, which is a chain of natural sugars throughout the body that can accumulate around cancer cells, inhibiting other therapies. PEGPH20 is designed to degrade HA to improve the access to tumor cells for chemotherapy, monoclonal antibodies and other immuno-therapy agents. For more information about these studies and other Halozyme news, please visit http://www.halozyme.com/Newsroom.
PEGPH20 is an investigational PEGylated form of Halozyme's proprietary recombinant human hyaluronidase under clinical development for the potential systemic treatment of tumors that accumulate hyaluronan.
FDA granted orphan drug designation to PEGPH20 for treatment of pancreatic cancer and fast track for PEGPH20 in combination with gemcitabine and nab-paclitaxel for the treatment of metastatic pancreatic cancer. Additionally, the European Commission, acting on the recommendation from the Committee for Orphan Medicinal Products of the European Medicines Agency, designated investigational drug PEGPH20 an orphan medicinal product for the treatment of pancreatic cancer.
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen and AbbVie for its drug delivery platform, ENHANZE™, which enables biologics and small molecule compounds that are currently administered intravenously to be delivered subcutaneously. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.
Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the possible activity, benefits and attributes of PEGPH20, the possible method of action of PEGPH20, its potential application to improve cancer therapies and statements concerning future actions relating to the development of PEGPH20) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected expenditures and costs, unexpected results or delays in development and regulatory review, regulatory approval requirements, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2015.
SOURCE Halozyme Therapeutics, Inc.